CEO Today USA Awards

73 www.ceotodaymagazine.com CEO Today USAAwards 2018 MASSACHUSETTS CHRIS SIMON CEO of Haemonetics ABOUT CHRIS SIMON Chris Simon was appointed CEO May 16, 2016. Previously, he served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. He brings more than 20 years of experience helping businesses transform and grow. Mr. Simon was the lead partner for the strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the company’s business and markets. Together with management and the board of directors, he co-architected the strategic plan that the company is now implementing. He was with McKinsey since 1993. Before that he served in commercial and operating roles at Baxter Healthcare Corporation, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School. www.haemonetics.com FIRM PROFILE In 1971, Haemonetics founder Jack Latham had a vision to bring together a commitment to quality and customer service with innovation in building a company to produce blood fractionation devices. Mr. Latham began his company by manufacturing and selling one perfectly designed component for a new blood collection device: a centrifuge disposable called the “Latham Bowl” that could automate the separation of blood. He constructed his company’s values on the belief that blood was a medical drug that needed to be respected and missteps in that regard caused considerable harm to patients. At the core of these values was his commitment to protecting patient’s safety. Mr. Latham knew the dangers patients can experience with whole blood transfusion, understood the potential of transfused fractionated blood products to help minimize those risks, and trusted his device would make this possible on a large scale for the benefit of patients everywhere. With that drive, he laid the foundation of what would become Haemonetics Corp. Haemonetics Corporation is now the global leader in blood management solutions. Our comprehensive portfolio of devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain — from plasma and blood collectors to hospitals. We believe that through proper blood management, our portfolio of products and services helps to prevent a transfusion for the patient who doesn’t need one and provides the right blood product, at the right time, in the right dose to the right patient who does. We began our odyssey of success in 1971 with devices and consumables, which changed the way blood was collected and processed at plasma and blood collection centers, as well as in the surgical suite. As industry needs have changed, we have evolved from a medical device company focused on blood processing systems to our current position as THE Global Leader in Blood Management Solutions. Today, as we enter our fifth decade, we believe that we are uniquely poised to transform the practice of blood management globally. We are committed to providing investors with the information they need to make informed investing decisions. In this section, you can access stock details, key financial data — such as quarterly results and SEC filings — tools to assemble your own investor kit, a list of our analysts, corporate governance information, and more.